\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe ISIDORe consortium has recently launched a call for proposals to support scientists with an interest in SARS-CoV-2 and COVID-19. This open call is a cascade funding initiative offering third parties the opportunity to make use of transnational access to ISIDORe services free of charge. Applications will be evaluated, selected and implemented on a rolling basis as long as funding remains available.
You can request transnational access to ISIDORe for research focused on: Surveillance & epidemic risk management; Understanding SARS-COV-2 & COVID-19; Diagnostics; Therapeutics; Vaccines; Social sciences & epidemiology
More information on the specific topics and how to apply on the project website.
The Horizon Europe funded project ISIDORe assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials. By giving scientists access to the whole extent of its facilities, cutting-edge services and advanced equipment, the project aims to accelerate the generation of new knowledge and intervention tools in order to enhance Europe’s capacity for controlling (re)emerging and epidemic infectious diseases.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The LDT4SSC (Local Digital Twins for Smart and Sustainable Communities) project has opened a new cascade funding call to local network of cities, regions, and digital innovators. This call supports co-funding for three Work Strands with a minimum available budget of 10.8 Million euros: - Work strand 1 - interconnecting existing LDTs: At least... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
